Related Experiment Video
Updated: Sep 10, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Recurrent Checkpoint Inhibitor-Related Pneumonitis Refractory to Corticosteroid Treatment: A Case Report and
Jinyu Yu1,2, Xuanjun Liu3,4, Xingjiao Ma4,5
1Department of Medical Oncology and Radiation Sickness, Peking University Third Hospital, Beijing, 100191, People's Republic of China.
Background:
Immune checkpoint inhibitors (ICIs) are antibodies that activate the immune system to kill tumor cells and have been widely used in oncology. However, dysregulated immune activation may result in the attack of normal tissues and organs, leading to immune-related adverse events (irAEs). Corticosteroid-refractory irAE pneumonitis severely threatens patient survival and is characterized by a lack of high-level evidence-based management guidelines, highlighting the need for increased scrutiny in this area.
Case Presentation:
This article presents the diagnosis and treatment of a patient with lung squamous cell carcinoma who developed recurrent corticosteroid-refractory grade 3 checkpoint inhibitor- related pneumonitis (CIP) during treatment with the ICI tislelizumab. The management approach included the use of intravenous immunoglobulin (IVIG) and mycophenolate mofetil (MMF). The case is thoroughly analyzed and discussed, accompanied by a review of relevant literature.
Conclusion:
IVIG and MMF showed effectiveness in corticosteroid-refractory CIP, and further investigation is warranted to establish standardized guideline and to optimize therapeutic drug monitoring for immunosuppressive agents.
Related Concept Videos
COPD: Management Using Bronchodilators and Corticosteroids
Pneumothorax-II
Clinical Manifestations:
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...

